-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $260

Benzinga·05/05/2026 13:11:00
Listen to the news
Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $245 to $260.